“So, over the next year or so, as we collect and finalize our data, that is really the anticipation of it.”

In context

“e ACIP decision. Dr. Albert Bourla: Maybe Angela can answer that. The question was, do you expect the share decision to have a big impact on RSV and also do we expect in the U.S. and also do we expect any impact, excluding the U.S.? Angela Hwang: Sure. So first of all, we’re really excited about the approval for our RSV older adult vaccine. And the way I would see this shared clinical decision-making is just that it is a step towards the full routine recommendation that we anticipate, so. And I think that there is -- the way to look at it is that it’s a short-term effect. We do expect that with more data that will emerge -- be emerging out of our clinical program, that we’ll have an additional opportunity to go back to the ACIP and actually get the routine recommendation that we hope for. So, over the next year or so, as we collect and finalize our data, that is really the anticipation of it. So, it doesn’t change the full opportunity for this particular vaccine. It doesn’t change the peak. It just means that it takes us a little bit longer to get to the peak because of the shared clinical decision-making that -- that extra step that we have to take right now. Dr. Albert Bourla: And what about the ex-U.S.? Angela Hwang: Ex-U.S., actually, we had a different filing. We were able to get both maternal and older adult at the same time. So I think you see slightly different dynamics there and that here in the U.S., our maternal vaccine will be launching later. But in ex-U.S. and in Europe, they will be launching at the same time. And those vaccine technical committees have not opined yet on those recommendations, in particular in terms of the utilization. And so, we’ll await that.”